| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Icosavax Inc. Common Stock (NASDAQ: ICVX)
ICVX Technical Analysis
4
| As on 9th Jun 2023 ICVX STOCK Price closed @ 9.47 and we RECOMMEND Sell for LONG-TERM with Stoploss of 9.63 & Strong Sell for SHORT-TERM with Stoploss of 18.48 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ICVXSTOCK Price
| Open | 9.70 | Change | Price | % |
| High | 9.93 | 1 Day | -0.13 | -1.35 |
| Low | 9.37 | 1 Week | -0.43 | -4.34 |
| Close | 9.47 | 1 Month | 3.96 | 71.87 |
| Volume | 71800 | 1 Year | -12.37 | -56.64 |
| 52 Week High 24.62 | 52 Week Low 2.32 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ICVX Daily Charts |
ICVX Intraday Charts |
Whats New @ Bazaartrend |
ICVX Free Analysis |
|
|
ICVX Important Levels Intraday
| RESISTANCE | 10.55 |
| RESISTANCE | 10.20 |
| RESISTANCE | 9.99 |
| RESISTANCE | 9.78 |
| SUPPORT | 9.16 |
| SUPPORT | 8.95 |
| SUPPORT | 8.74 |
| SUPPORT | 8.39 |
ICVX Forecast May 2024
| 4th UP Forecast | 29.65 |
| 3rd UP Forecast | 23.18 |
| 2nd UP Forecast | 19.18 |
| 1st UP Forecast | 15.18 |
| 1st DOWN Forecast | 3.76 |
| 2nd DOWN Forecast | -0.24 |
| 3rd DOWN Forecast | -4.24 |
| 4th DOWN Forecast | -10.71 |
ICVX Weekly Forecast
| 4th UP Forecast | 17.58 |
| 3rd UP Forecast | 14.98 |
| 2nd UP Forecast | 13.37 |
| 1st UP Forecast | 11.76 |
| 1st DOWN Forecast | 7.18 |
| 2nd DOWN Forecast | 5.57 |
| 3rd DOWN Forecast | 3.96 |
| 4th DOWN Forecast | 1.36 |
ICVX Forecast2024
| 4th UP Forecast | 54.5 |
| 3rd UP Forecast | 40.06 |
| 2nd UP Forecast | 31.13 |
| 1st UP Forecast | 22.21 |
| 1st DOWN Forecast | -3.27 |
| 2nd DOWN Forecast | -12.19 |
| 3rd DOWN Forecast | -21.12 |
| 4th DOWN Forecast | -35.56 |
Icosavax Inc. Common Stock ( NASDAQ USA Symbol : ICVX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ICVX Business Profile
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-A12, an respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-121, a vaccine candidate with RSV target; IVX-241, a vaccine candidate with hMPV target; IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2^ target indication; and IVX-421, a variant RBD antigen with SARS-CoV-2^ target indication. The company was incorporated in 2017 and is headquartered in Seattle, Washington. Address: 1616 Eastlake Avenue E., Seattle, WA, United States, 98102
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service